| Description | Triheptanoin (IND 106011) is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1. |
| Synonyms | UX 007, IND106011, 三庚酸甘油脂, UX007, UX-007, IND 106011, IND-106011 |
| molecular weight | 428.6 |
| Molecular formula | C24H44O6 |
| CAS | 620-67-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/ml (116.66 mM) |
| References | 1. Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review. Mol Genet Metab. 2015 Sep-Oct;116(1-2):53-60. doi: 10.1016/j.ymgme.2015.06.006. Review. Erratum in: Mol Genet Metab. 2015 Nov;116(3):221. PubMed PMID: 26116311. 2. Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, Conway R, Enns GM, Starr J, Wang R, Abdenur JE, Sanchez-de-Toledo J, Marsden DL. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab. 2016 Nov;119(3):223-231. doi: 10.1016/j.ymgme.2016.08.008. PubMed PMID: 27590926. 3. Schwarzkopf TM, Koch K, Klein J. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin. Neuroscience. 2015 Aug 6;300:201-9. doi: 10.1016/j.neuroscience.2015.05.014. PubMed PMID: 25982559. 4. Nguyen TD, Shingu Y, Amorim PA, Schwarzer M, Doenst T. Triheptanoin Alleviates Ventricular Hypertrophy and Improves Myocardial Glucose Oxidation in Rats With Pressure Overload. J Card Fail. 2015 Nov;21(11):906-15. doi: 10.1016/j.cardfail.2015.07.009. PubMed PMID: 26209001. |